Skip to main content

Table 1 List of microRNA’s targeted by studies of breast cancer patients displaying cardiotoxicity following treatment with Anthracyclines and comparison of expression with control groups

From: A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

MicroRNA Reference Subjects (Healthy Controls/ Chemotherapy group) Treatment Period Tested Expression Change to Control group Differential Expression Proposed Role
Section A
 hsa-miR-29a-3p [33] 17/17 DOX 6 months Increased + 5 RE Cardiac repair
 hsa-miR-199a-3p [28] 38/7 NAC 2 cycles Increased + 1.2 FC Cardiomyocyte regeneration
 hsa-miR-1273 g-3p [34] 20/20 AC PT Decreased −0.52Log2ΔCt Regulatory function of TGF-β pathway
 hsa-miR-4638-3p [34] 20/20 AC PT Decreased −1.37 Log2ΔCt Regulatory function of TGF-β pathway
Section B
 hsa-miR-34a-5p [33] 17/17 DOX 6 months Increased + 40 RE Cardiac repair
[28] 38/7 NAC 2 cycles Increased + 24.3 FC  
[32] 44/12 DOX 3 months No significant change  
[32] 14/18 EPI 3 months No significant change  
 hsa-miR-1 [31] 46/10 DOX 4 cycles Increased + 2Log2FC Cardiac hypertrophy
[28] 38/7 NAC 3 months No significant change  
[32] 44/12 DOX 3 months No significant change  
[32] 14/18 EPI 3 months No significant change  
 hsa-miR-17-5p [29] 170/9 EC-D 8 cycles No significant change Pro-angiogenic
[30] 346/19 EC-D 8 cycles Decreased 0.213 OR  
 hsa-miR-19a [29] 170/9 EC-D 8 cycles Increased + 2.1 RE Pro-angiogenic
[30] 346/19 EC-D 8 cycles No significant change  
 hsa-miR-122-5p [32] 44/12 DOX 3 months Increased + 3 ΔΔCt Coronary disease
[32] 14/18 EPI 3 months No significant change  
 hsa-miR-130a [29] 170/9 EC-D 8 cycles No significant change Cardiomyopathy
[30] 346/19 EC-D 8 cycles No significant change  
[35] 60/12 EC-D + T 15 months Increased + 4 RE  
 hsa-miR-378 [29] 170/9 EC-D 8 cycles No significant change Pro-angiogenic
[30] 346/19 EC-D 8 cycles Decreased 0.278 OR  
 hsa-miR-423 [28] 38/7 NAC 3 months Increased + 1.3 FC Progressive heart failure
[31] 46/10 DOX 4 cycles No significant change  
[33] 17/17 DOX 6 months Increased + 6.5 RE  
 hsa-miR-499 [32] 44/12 DOX 3 months Increased + 2 ΔΔCt Acute myocardial infarction
[28] 38/7 NAC 3 months No significant change  
[32] 14/18 EPI 3 months No significant change  
[33] 17/17 DOX 6 months Increased + 15 RE  
 hsa-miR-885-5p [32] 44/12 DOX 3 months Increased + 2 ΔΔCt Liver toxicity
[32] 14/18 EPI 3 months No significant change  
Section C
 hsa-Let-7b [29] 170/9 EC-D 8 cycles No significant change Pro-angiogenic
[30] 346/19 EC-D 8 cycles No significant change  
 hsa-miR-17-3p [29] 170/9 EC-D 8 cycles No significant change Cardiac hypertrophy
[30] 346/19 EC-D 8 cycles No significant change  
 hsa-miR-18a [29] 170/9 EC-D 8 cycles No significant change Oncogenic inhibitor
[30] 346/19 EC-D 8 cycles No significant change in breast cancer
 hsa-miR-19b-1 [29] 170/9 EC-D 8 cycles No significant change Inflammatory
[30] 346/19 EC-D 8 cycles No significant change response
 hsa-miR-92a [29] 170/9 EC-D 8 cycles No significant change Pro-angiogenic
[30] 346/19 EC-D 8 cycles No significant change  
 hsa-miR-133a [28] 38/7 NAC 3 months No significant change Acute myocardial infarction
 hsa-miR-133b [31] 46/10 DOX 4 cycles No significant change Acute myocardial
[28] 38/7 NAC 3 months No significant change infarction
 hsa-miR-146a [31] 46/10 DOX 4 cycles No significant change Inflammatory response
 hsa-miR-208a [28] 38/7 NAC 3 months No significant change Cardiomyocyte
[31] 46/10 DOX 4 cycles No significant change damage
 hsa-miR-208b [28] 38/7 NAC 3 months No significant change Cardiomyocyte
[31] 46/10 DOX 4 cycles No significant change damage
 hsa-miR-296 [29] 170/9 EC-D 8 cycles No significant change Angiogenesis
[30] 346/19 EC-D 8 cycles No significant change  
Section D
 hsa-miR-20a [29] 170/9 EC-D 8 cycles Increased + 1.1 RE Pro-angiogenic
[30] 346/19 EC-D 8 cycles Decreased 0.264 OR  
 hsa-Let-7f [29] 170/9 EC-D 8 cycles Increased + 1.1 RE Pro-angiogenic
[30] 346/19 EC-D 8 cycles Decreased 0.228 OR  
 hsa-miR-126 [29] 170/9 EC-D 8 cycles Increased + 1.5 RE Pro-angiogenic
[33] 17/17 DOX 6 months Increased + 28 RE  
[30] 346/19 EC-D 8 cycles Decreased 0.358 OR  
[28] 38/7 NAC 3 months Increased + 1.3 FC  
 hsa-miR-210 [29] 170/9 EC-D 8 cycles Increased + 1.2 RE Pro-angiogenic
[30] 346/19 EC-D 8 cycles Decreased 0.475 OR  
  1. Part A: microRNAs with significant changes in expression with no independent replication, Part B: microRNAs with significant changes in expression and independent replication (whether significant or not), Part C: microRNAs with no significant changes in expression detected, Part D: microRNAs with contradictory evidence of direction of expression change in independent replication. Key: EC-D = Epirubicin + Cyclophosphamide (4 cycles) followed by Docetaxel (4 cycles), DOX = Doxorubicin, EPI = Epirubicin, NAC = Cyclophosphamide + Epirubicin (4 cycles) followed by Paclitaxel (9 to 12 weeks), AC = Anthracycline chemotherapy (not specified), PT = Post-treatment, RE = Relative Expression, FC = Fold Change, OR = Odds Ratio